New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
08:19 EDTONVOOrganovo reports Q3 EPS (7c) vs. (20c) a year ago
Reports Q3 revenue $135K, one estimate $180K. The company said its decrease in revenue from prior year levels reflects declining activity under an existing collaborative agreement and the conclusion of a previous collaborative research agreement during the quarter, partially offset by increasing revenue contributions from three recently signed agreements. Organovo is a development stage company, and does not expect product-based revenue until the commercial release of its liver toxicity assay product, currently planned to be before the end of November.
News For ONVO From The Last 14 Days
Check below for free stories on ONVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
09:16 EDTONVOOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTONVOOrganovo jumps 19% to $9.13 following agreement with J&J unit
08:39 EDTONVOOrganovo enters 3D bio-printed tissue agreement with J&J unit
Organovo (ONVO) announced that it has entered into an agreement with Janssen Research and Development, a pharmaceutical company of Johnson & Johnson (JNJ), to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the company’s work in 3D liver tissue for toxicity testing. Terms were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use